cyrilzakka/clinical-trials huggingface dataset:
Human TECAR on Exercise Preconditioning and Post-exercise Recovery

TECAR therapy (Transfer of Energy Capacitive and Resistive) is a type of diathermy that uses radiant energy to generate endogenous heat. However, to the date there are no studies investigating the effects of TECAR therapy on exercise preconditioning and post-exercise recovery in humans. Therefore, the aim of this project is to assess the effects of different treatment protocols of TECAR therapy on. exercise preconditioning and post-exercise recovery in humans

Fifty male healthy volunteers will be enrolled in a randomized, double-blind (participants and assessors), controlled trial. Volunteers will be allocated in 5 groups of 10 participants each: 1 - Sham-control (fake intervention - massaging with one of the Human TECAR probes with the device turned off before or after the eccentric exercise protocol depending on randomization); 2 - Capacitive mode before exercise (preconditioning); 3 - Resistive mode before exercise (preconditioning); 4 - Capacitive mode after exercise (recovery); and 5 - Resistive mode after exercise (recovery). The treatment target will be the knee extensors muscles (quadriceps).

A standardized knee extension eccentric exercise protocol performed in the isokinetic dynamometer (Biodex System 4) will be used in order to exercise induce skeletal muscle fatigue and damage.

Volunteers will be treated with Human TECAR in a single treatment session, with 10 minutes length, that will be carried out immediately before or immediately after the exercise protocol according to the randomization.

Eligibility Criteria:
Inclusion Criteria:

* Physically active male participants;
* Do not present a history of musculoskeletal injury in the regions of the hips, knees and calves in the month preceding the study;
* Are not using pharmacological agents;
* Voluntarily commit to participate in all stages of the study.

Exclusion Criteria:

* Present musculoskeletal or joint injuries during data collection;
* Present history of musculoskeletal injury in the regions of the hips, knees and calves in the month preceding the study.
Evaluation of 18F-TFB PET/CT Scan in Patients with Differentiated Thyroid Cancer

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

PRIMARY OBJECTIVES:

I. Evaluate fluorine F 18 tetrafluoroborate (18F-TFB) positron emission tomography (PET)/computed tomography (CT) imaging in patients with intermediate or high risk differentiated thyroid cancer (DTC) and compare to the current clinical standard.

II. Assess the impact of 18F-TFB PET/CT on clinical management.

OUTLINE:

Patients receive fluorine F 18 tetrafluoroborate intravenously (IV) and undergo PET/CT scan on study.

Eligibility Criteria:
Inclusion Criteria:

* Subject has biopsy-proven papillary or follicular thyroid cancer
* Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan
* Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan
* Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent)
* Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min)
* Age 18 or older
* Ability to understand a written informed consent document, and the willingness to sign it
* Subject is not pregnant

Exclusion Criteria:

* Contrast-enhanced CT within 4 last weeks
* Amiodarone within last 4 months
* Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks
* Unable to lie flat, still or tolerate a PET scan
* Applied betadine, iodoform, or quick tanning products to skin within last two weeks
* If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25
* Taken anti-thyroid medication within 1 week
* Subject is breastfeeding
* Positive pregnancy test
Development and Application of an Artificial Intelligence-driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis

The clinical trial titled "Development and Application of an Artificial Intelligence-Driven Accurate Identification Model for Gastric Cancer Lymph Node Metastasis" aims to enhance the detection and treatment of gastric cancer through the utilization of cutting-edge artificial intelligence (AI) technology. This study will develop an AI-driven model designed to accurately identify lymph node metastasis in patients with gastric cancer, which is crucial for staging the disease and planning effective treatment strategies.

The trial will involve a multidisciplinary team of oncologists, radiologists, data scientists, and AI experts who will collaborate to create a robust and precise identification system. Participants will undergo standard diagnostic procedures, and the AI model will analyze imaging and pathological data to predict lymph node involvement.

By comparing the AI model's predictions with traditional diagnostic methods, the study seeks to validate the model's accuracy and efficiency. This approach is expected to improve early detection rates, reduce diagnostic errors, and ultimately lead to better clinical outcomes for patients with gastric cancer. The successful implementation of this AI-driven model could revolutionize the current standards of care and serve as a blueprint for integrating AI technologies in other cancer diagnoses and treatments.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of Gastric Cancer: Confirmed diagnosis of gastric cancer, either newly diagnosed or recurrent.
2. Lymph Node Involvement: Suspected or confirmed involvement of lymph nodes, as indicated by imaging studies or pathology reports.
3. Age: Patients aged 18 years or older.
4. Performance Status: An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, indicating a functional status that allows participation in the study.
5. Informed Consent: Ability to provide written informed consent to participate in the study.

Exclusion Criteria:

1. Pregnancy or Lactation: Pregnant or lactating women, due to potential risks to the fetus or infant.
2. Severe Comorbid Conditions: Presence of severe comorbid medical conditions that could interfere with the study or pose additional risks.
3. Previous AI-Driven Diagnostic Intervention: Prior use of any AI-driven diagnostic models specifically for gastric cancer lymph node metastasis.
4. Inability to Comply: Inability or unwillingness to comply with study procedures, including follow-up visits and data collection.
5. Mental or Cognitive Impairment: Conditions that impair the ability to provide informed consent or participate effectively in the study.
Chronic Pain After Amputation

This trial will test the effectiveness of amitriptyline in relieving chronic pain of adults that have had an amputation

This double-masked placebo controlled trial will randomize patients (n=125) who are 6 months or more after amputation and have a 3 or more month history of pain to a daily dose of amitriptyline or a placebo for 6 weeks. Patients will receive a complete functional neurological examination by one of the study physicians or nurses masked to their treatment assignment. Study participants will also be interviewed by telephone to assess pain, pain interference with activities, physical and mental health, and number of health care visits for pain, at the beginning and end of the six-week trial and four months later.

Eligibility Criteria:
Inclusion Criteria:

* Amputation six months ago or longer
* Pain for 3 months or longer

Exclusion Criteria:

* History of cardiovascular disease, seizures, or glaucoma
* Currently taking antidepressant medications
* Currently hyperthyroid or taking thyroid medication
* Currently pregnant
Timing Impact of Early vs. Late Cranioplasty on Hemicraniectomy Outcomes

This prospective, randomized study aims to comprehensively evaluate the impact of cranioplasty timing on postoperative complications and long-term functional outcomes following decompressive hemicraniectomy (DHC). The primary endpoint focuses on comparing the rates of various postoperative complications, including infection, seizures, return to the operating room, and the need for ventriculoperitoneal shunting, between patients undergoing standard of care cranioplasty (\>3 months after DHC) and those receiving early cranioplasty (within 8 weeks).

This prospective, randomized study aims to comprehensively evaluate the impact of cranioplasty timing on postoperative complications and long-term functional outcomes following decompressive hemicraniectomy (DHC). The primary endpoint focuses on comparing the rates of various postoperative complications, including infection, seizures, return to the operating room, and the need for ventriculoperitoneal shunting, between patients undergoing standard of care cranioplasty (\>3 months after DHC) and those receiving early cranioplasty (within 8 weeks).

The primary endpoint involves a comprehensive evaluation of long-term functional outcomes at 6 months post-injury ("injury" defined as "acute traumatic injury or source of increased intracranial pressure secondary to stroke or intracranial hemorrhage"). This assessment aims to determine whether the timing of cranioplasty influences patients' neurological recovery, cognitive function, and overall quality of life. By comparing the outcomes of patients who undergo standard of care cranioplasty with those who undergo early cranioplasty, the study seeks to provide valuable insights into the potential benefits of the latter approach.

The findings of this research hold the potential to guide clinical practice and inform decision-making for patients who have undergone DHC. By considering a range of complications and incorporating a robust statistical framework, the study contributes to a more nuanced understanding of the advantages and disadvantages associated with different cranioplasty timing strategies.

Eligibility Criteria:
Inclusion Criteria:

* Adults of age greater than or equal to 18 years at the time of acute traumatic injury or source of increased intracranial pressure secondary to stroke or intracranial hemorrhage necessitating decompressive hemicraniectomy (DHC)
* Patient's cranial flap fulfills Craniectomy Contour Class A or B after 4 weeks postoperatively (doi:10.1227/ons.0000000000000689)
* Medically optimized for general anesthesia/surgery

Exclusion Criteria:

* Active systemic infection in weeks 6-8 post-DHC leading up to cranioplasty (e.g. pneumonia, urinary tract infection, soft tissue infection, bacteremia)
* Cranial infection in the post-DHC period
* Patient deemed not appropriate for early cranioplasty by attending neurosurgeon
* Patient mortality prior to 8 weeks post-injury ("injury" defined as "acute traumatic injury or source of increased intracranial pressure causing brain injury secondary to stroke or intracranial hemorrhage")
Oregon Supplement: Supporting Sustainable Positive Interactions in the Child Welfare System: The R3 Supervisor Strategy

This administrative supplement capitalized on the preliminary positive outcomes from the primary parent grant award (R01DA040416), and lessons learned from the implementation of the R3 Supervisor Strategy (R3) throughout the participating four regions (12 counties) in Tennessee. This project aimed to pilot the implementation of R3 with a new sample, a cohort of counties in Oregon particularly affected by the current opioid epidemic, for potential scale-up.

Oregon currently is experiencing a crisis within its Child Welfare System (CWS), with combined challenges within the workforce and departmental support, and a staggering rise in referrals for parental substance abuse. The R3 Supervisor Strategy (R3) provides training, consultation, and fidelity-monitoring to supervisors in the CWS, who are centrally positioned between caseworkers (who have daily interactions with CWS-involved families) and leadership (who make decisions that affect the organization in which families receive services). Supervisors are trained to implement key reinforcement strategies that make up the three Rs including reinforcement of (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement. R3 is relatively easy to learn and sustain and has demonstrated promise in improving CWS outcomes in the parent grant award (R01DA040416). Because many of the counties most impacted by the opioid crisis are rural and under-resourced, an approach like R3 provides the opportunity to introduce evidence-based strategies to these regions where it otherwise is not feasible to adopt more intensive services. This study utilized the same Hybrid Type II design as its parent grant in which supervisors and caseworkers from two Oregon counties particularly affected by the substance abuse crisis were recruited to to provide a pilot assessment of the effectiveness of R3 with an emphasis on referrals for opioid and methamphetamine use (Aim 1). In doing so, the study also sought to modify the R3 training materials to emphasize examples of working with families referred for parental substance abuse (Aim 2) and replicate the preliminary findings from the parent grant, providing pilot data for a larger state scale-up of R3. This administrative supplement allowed an initial assessment to identify if R3's strategies are profound enough to impact the most challenging systems, faced with the most challenging public health crisis presented currently-the impact of the opioid epidemic on families.

Eligibility Criteria:
Inclusion Criteria:

* Oregon Child welfare workforce employee in a participating county.

Exclusion Criteria:

- Contract Workers
Study of Light Treatment and Laser Treatment for Melasma

The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of melasma lesion measuring at least 4 square centimeters.
* Age 18-75 years.
* Good health.
* Willingness and ability to understand and provide informed consent for participation in the study.
* Ability to communicate with the investigator.
* Must be willing to forgo other treatment options for melasma during the course of the study.

Exclusion Criteria:

* Inability to understand the protocol or to give informed consent.
* Mental illness.
* Under 18 years of age and over 75 years of age.
* Laser treatment in the last 6 months before enrollment.
* Isotretinoin within the past year.
* Lidocaine allergy.
* History of herpes simplex viral infection.
* Concurrent active disease to facial area (i.e acne).
* Bleeding disorder.
* History of abnormal wound healing.
* History of abnormal scarring.
HIIT on Overweight Middle-aged Adults

36 middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week) and the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

Aging, obesity, have been shown to lead to higher oxidative stress and chronic inflammation. However, high-intensity interval training (HIIT) has anti-inflammatory and anti-obesity benefits. Different training prescriptions may also affect improvements. Therefore, this study will explore the optimal HIIT prescription to improve fat, inflammation, metabolism, and exercise performance in overweight middle-aged and older adults. Thirty-six middle-aged with overweight adults were divided into three groups: 1. L-HIIT group: the long-interval HIIT group (4 × 4 min Exercise/4 min Rest), 2. M-HIIT group: the medium-interval HIIT group (8 × 2 min Exercise/2 min Rest), 3. Control group: no exercise intervention. All groups carried out the training stage for 8 weeks (three sessions per week), then the detraining stage for 4 weeks in order to investigate the effects induced by different HIIT interventions on inflammation, metabolic adaptation, anti-fatigue and exercise performance, and fat loss.

Eligibility Criteria:
Inclusion Criteria:

* Recruit people who are overweight or obese (BMI between 24-35) who are 20-65 years old and have no exercise habits in a sitting lifestyle.

Exclusion Criteria:

* If there are any of the following circumstances, they are not allowed to participate in this research and are included in the listing conditions of this case:

  1. Have smoking and drinking habits.
  2. People who have stroke, type 1 and type 2 diabetes, neuromuscular disease, so that they cannot participate in physical activities.
  3. Chronic obstructive lung disease, asthma, interstitial lung disease or alveolar cyst fibrosis.
  4. Metabolic diseases include thyroid disease, kidney disease (kidney, bladder stones) or liver disease.
  5. Those with arrhythmia, a rhythm regulator, severe cardiovascular disease, peripheral vascular disease or cerebrovascular disease.
  6. People with epilepsy and rheumatoid arthritis.
  7. Those who have implanted artificial joints in the past six months and have had recent surgery.
  8. Migraine, acute thrombosis and hernia.
  9. Those who have engaged in strenuous exercise or have muscle aches within 24 hours before the experiment.
  10. People who feel unwell due to other reasons during the experiment.
  11. People with severe food allergies.
  12. Have hospitalization records within three months.
  13. People with cognitive impairment.
  14. Take any drugs that affect the function of the nervous system.
Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD

The broad, long-term objective of the current research is to improve treatment outcomes for individuals with comorbid posttraumatic stress disorder (PTSD) and alcohol abuse and dependence (AUD).

The purpose of which is to evaluate changes in both PTSD symptoms and alcohol use and cravings associated with Cognitive Processing Therapy (CPT) or Relapse Prevention (RP) treatment in individuals with PTSD/AUD, along with mediators and moderators of outcomes.

The study will randomize 235 PTSD/AUD participants recruited from the VA and from the community to CPT, RP, or Interactive Voice Response (IVR) assessment only (AO). Those in the AO condition will be re-randomized after the treatment phase to either RP or CPT. Individuals will be assessed pretreatment, immediately post-treatment, 3-, 6-, 9-, and 12-months post-treatment and will monitor symptoms daily throughout treatment.

Prior research has established that PTSD and AUD are frequently comorbid.

Although combined treatments have been developed, they are complex and lengthy with mixed results as to their efficacy. Excellent treatments exist for PTSD or AUD alone, however, it has not been adequately addressed to what extent these treatments are effective in treating comorbid symptom presentations. To address this research gap, the investigators will evaluate two widely accepted treatments for each respective disorder; Cognitive Processing Therapy (CPT) an effective PTSD treatment and Relapse Prevention (RP), a widely used effective AUD treatment.

The investigators will build on our prior work using a daily telephone Interactive Voice Response (IVR) system to test models of self-medication and the sequence of symptom change for both primary and secondary symptom targets associated with each therapy.

Creating a more comprehensive model of symptom change in PTSD and alcohol use with widely used selective treatments is critical in testing theories of PTSD/AUD, evaluating these treatments for use with PTSD/AUD, and implementing these therapies with PTSD/AUD patients in standard clinical practice

Eligibility Criteria:
Inclusion Criteria:

* Men and women age ≥ 18 years with a current DSM-V diagnosis of alcohol abuse/dependence
* Recent alcohol consumption for at least 2 weeks in the past 30 day period OR at least 2 days of heavy drinking in the past 30 day period
* Desire to abstain from alcohol
* Current DSM-V (Diagnostic and Statistical Manual of Mental Disorders) diagnosis of PTSD
* Capacity to provide informed consent
* English fluency

Exclusion Criteria:

* Men and women with an unstable psychiatric medication regimen
* Current trauma-focused mental health treatment (MH) or behaviorally focused alcohol dependence (AD) AD/MH treatment in the past 30 days
* Suicide attempt or suicidal ideation with intent or plan, or self-harm in the past month
* Presence of a psychotic disorder or uncontrolled Bipolar Disorder
* Signs or symptoms of alcohol withdrawal at the time of initial consent
Efficacy of Twinkle Eyez Supplementation in Improving Ocular Health and Immunity

This is a randomised, double-blind, placebo-controlled study that recruited 110 participants. The objectives of this study are to determine the dietary intake levels of lutein and zeaxanthin among precipitants. In additionally, this study also aimed to determine the efficacy of twinkle eyez supplementation in improving ocular health and immunity. The participant are required to take one sachet of twinkle eyez supplements or placebo for 20 days. The outcomes were assessed by food frequency questionnaire (FFQ), Ocular Surface Disease Index (OSDI), the Immune Status Questionnaire (ISQ), and the Visual Analogue Scale (VAS).


Eligibility Criteria:
Inclusion Criteria:

* presence of dry eye symptoms
* age 18 years or older
* ability to comprehend the study protocol and information provided by the investigators
* provision of informed consent.

Exclusion Criteria:

* ongoing medical treatment for ocular diseases or conditions
* use of certain medications, including hormone replacement therapy, antidepressants, and treatments for high blood pressure, acne, birth control, and Parkinson's disease
* history of eye surgery within the past three months
* pregnancy or lactation
EAGLE Trial CADDIE Artificial Intelligence Endoscopy

The EAGLE study is a prospective randomized controlled multicenter parallel design trial, for the assessment of clinical performance of the CADDIE device and to confirm that the device performs as expected.

The EAGLE study will be conducted with a parallel design. Patients who meet the study inclusion/exclusion criteria will be randomized in a 1:1 ratio to receive either computer-aided colonoscopy (CADDIE Arm) using CADDIE or standard colonoscopy without CADe (Control Arm). All resected polyps will be submitted for histologic examination.

Eligibility Criteria:
Inclusion Criteria:

1. Screening or surveillance colonoscopy
2. Age 40 years or older
3. Informed consent

Exclusion Criteria:

1. Emergency colonoscopies
2. Inflammatory bowel disease (IBD)
3. Colorectal Cancer (CRC)
4. Previous Colorectal Cancer (CRC)
5. Previous colonic resection
6. Returning for a planned elective therapeutic colonoscopy.
7. Polyposis syndromes (familial adenomatous polyposis)
8. Contraindication for biopsy or polypectomy.